MARKET

AXGN

AXGN

Axogen Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.33
-0.71
-3.73%
Opening 14:15 01/22 EST
OPEN
18.85
PREV CLOSE
19.04
HIGH
19.19
LOW
18.30
VOLUME
97.61K
TURNOVER
--
52 WEEK HIGH
20.83
52 WEEK LOW
7.16
MARKET CAP
744.54M
P/E (TTM)
-29.3280
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Repair and Re-generation for Peripheral Nerve Market Size 2021 By Industry Expansion Strategies, Development Trends, Modest Analysis, Business Prospect, Regional Growth, End User Analysis and Forecast to 2025 Says Industry Research Biz
Jan 15, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Repair and Re-generation for...
The Express Wire · 01/15 07:17
Axogen reports Q4 and FY20 prelim revenue above consensus
Axogen ([[AXGN]] +1.7%) reported preliminary unaudited 4Q20 revenue of $32.4M (+15% Y/Y) vs. $29.52M consensus and FY20 revenue of $112.2M (+5% Y/Y) vs. $109.34M consensus.Axogen increased active accounts in Q4
Seekingalpha · 01/11 16:16
A Trio of Fast Growing Revenue Stock Picks
A Trio of Fast Growing Revenue Stock Picks, Stocks: MATX,WK,AXGN, release date:Jan 11, 2021
GuruFocus.com · 01/11 13:45
A Trio of Fast Growing Revenue Stock Picks
GuruFocus News · 01/11 12:51
*DJ Axogen Sees 2020 Revenue at Least $112.2 Million
Dow Jones · 01/11 12:01
*DJ Axogen: Year-Over-Year Revenue Growth Despite Continued Effect of Covid-19 Pandemic
Dow Jones · 01/11 12:01
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2020
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2020 revenue.
GlobeNewswire · 01/11 12:00
*DJ Axogen Sees 4Q Revenue at Least $32.4 Million
Dow Jones · 01/11 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AXGN. Analyze the recent business situations of Axogen Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AXGN stock price target is 21.33 with a high estimate of 24.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 217
Institutional Holdings: 44.73M
% Owned: 110.12%
Shares Outstanding: 40.62M
TypeInstitutionsShares
Increased
24
1.26M
New
33
2.07M
Decreased
46
3.64M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.08%
Healthcare Equipment & Supplies
+0.04%
Key Executives
Chairman/President/Chief Executive Officer/Director
Karen Zaderej
Chief Financial Officer
Peter Mariani
Chief Human Resource Officer
Maria Martinez
Chief Compliance Officer/General Counsel
Brad Ottinger
Vice President - Operations
Mike Donovan
Vice President
Erick DeVinney
Vice President
Mark Friedman
Other
Isabelle Billet
Other
Eric Sandberg
Other
Angelo Scopelianos
Lead Director/Independent Director
Amy Wendell
Director
Gregory Freitag
Director
Paul Thomas
Independent Director
Quentin Blackford
Independent Director
Mark Gold
Independent Director
Mark Stephen Gold
Independent Director
Alan Levine
Independent Director
Guido Neels
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
12/21/2009
Dividend USD 1
01/27/2010
--
Dividend USD 0.06
02/23/2005
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AXGN
AxoGen, Inc. offers surgical solutions for peripheral nerve injuries. The Company provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. Its portfolio of products includes Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector and Avive Soft Tissue Membrane. Along with these core surgical products, the Company also offers the AxoTouch Two-Point Discriminator, and AcroVal Neurosensory and Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation; assessing return of sensory, grip and pinch function; evaluating treatment interventions, and providing feedback to patients on nerve function. Its portfolio of products is available in the United States, Canada, the United Kingdom and several European and other countries. The Company's products are used by surgeons during surgical interventions to repair a range of nerve injuries throughout the body.
More

Webull offers kinds of AxoGen Inc stock information, including NASDAQ:AXGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXGN stock methods without spending real money on the virtual paper trading platform.